Papot, Emmanuelle and Tovar-Sanchez, Tamara and Woods, Joana and Thaurignac, Guillaume and Eriobu, Nnakelu and Borok, Margaret and Kaplan, Richard and Avihingsanon, Anchalee and Azwa, Iskandar and Grinsztejng, Beatriz and Kumarasamy, Nagalingeswaran and Sokhela, Simiso and Mpoudi-Etame, Mireille and Arriaga, Maria and Jacoby, Simone and Matthews, Gail V. and Losso, Marcelo H. and Khoo, Saye and Calmy, Alexandra and Kouanfack, Charles and Ayouba, Ahidjo and Petoumenos, Kathy and Venter, W. D. Francois and Delaporte, Eric and Polizzotto, Mark N. and Grp, COHIVE Study (2025) SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa. AIDS, 39 (4). pp. 448-456. ISSN 0269-9370, DOI https://doi.org/10.1097/QAD.0000000000004068.
Full text not available from this repository.Abstract
Objective:Data on the impact of coronavirus disease 2019 (COVID-19) in people with HIV (PWH) are lacking in resource-constrained settings. We utilized existing randomized clinical trials (RCTs) on antiretroviral therapies (ART) in HIV-1 infection to conduct a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurvey, between January and March 2021, while characterizing participants' features. Design:Cross-sectional serosurvey. Methods:Demographic characteristics, medical history and a serum sample were collected from consenting PWH. Samples were analyzed centrally for immunoglobulin G antibodies to recombinant nucleocapsid and spike proteins derived from SARS-CoV-2 using a Luminex based assay. Results:The 549 participants recruited in 9 sites across Africa had a median age of 40 years (interquartile range, IQR 34-45]); 63.0% (346) were female. All were on ART; 81.8% (449) had an HIV-1 viral load <50 copies/ml, with CD4+ cell count median at 478/mm3 (IQR 320-677]). None had received vaccination against SARS-CoV-2. Forty participants (7.3%) had a prior SARS-CoV-2 PCR testing, of whom 10 were positive (1.8%). Crude SARS-CoV-2 seroprevalence was 36.2% (95% confidence interval (CI) 32.2-40.4]). In the explorative multivariable analysis, comparison of the characteristics of PWH with a positive SARS-CoV-2 serology with those with a negative or indeterminate serology: PWH with a body mass index (BMI) >= 30 kg/m2 were more likely to have a positive serology than those with a BMI <25 (adjusted odds ratio (aOR) = 2.39 1.48-3.86], P < 0.001); and PWH living in Cameroon were less likely to have a positive serology. Conclusion:This study demonstrates a substantial seroprevalence level of SARS-CoV-2 in PWH in the first quarter of 2021, with a marked disparity with the number of COVID-19 PCR tests reported positive.
| Item Type: | Article |
|---|---|
| Funders: | UNSPECIFIED |
| Uncontrolled Keywords: | Coronavirus disease 2019; People with HIV; Randomized clinical trials; Serology |
| Subjects: | R Medicine > R Medicine (General) |
| Divisions: | Faculty of Medicine > Medicine Department |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 03 Oct 2025 07:39 |
| Last Modified: | 03 Oct 2025 07:39 |
| URI: | http://eprints.um.edu.my/id/eprint/47833 |
Actions (login required)
 |
View Item |
